Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: rationale and design of the PROMISE-AF phase II study

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
981kB
[thumbnail of Supplementary Material] Other (Supplementary Material)
46kB

Item Type:Article
Title:Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: rationale and design of the PROMISE-AF phase II study
Creators Name:Berlin, S., Goette, A., Summo, L., Lossie, J., Gebauer, A., Al-Saady, N., Calo, L., Naccarelli, G., Schunck, W.H., Fischer, R., Camm, A.J. and Dobrev, D.
Abstract:We designed a placebo controlled, double-blind, randomized, dose-finding phase II study on OMT-28 in the maintenance of sinus rhythm after electrical cardioversion (DCC) in patients with persistent atrial fibrillation (PROMISE-AF). OMT-28 is a first-in-class, synthetic analog of 17,18-epoxyeicosatetetraenoic acid, a bioactive lipid mediator generated by cytochrome P450 enzymes from the omega-3 fatty acid eicosapentaenoic acid. OMT-28 improves Ca(2+)-handling and mitochondrial function in cardiomyocytes and reduces pro-inflammatory signaling. This unique mode of action may provide a novel approach to target key mechanism contributing to AF pathophysiology. In a recent phase I study, OMT-28 was safe and well tolerated and showed favorable pharmacokinetics. The PROMISE-AF study (NCT03906799) is designed to assess the efficacy (primary objective), safety, and population pharmacokinetics (secondary objectives) of three different doses of OMT-28, administered once daily, versus placebo until the end of the follow-up period. Recruitment started in March 2019 and the study will include a total of 120 patients. The primary efficacy endpoint is the AF burden (% time with any AF), evaluated over a 13-week treatment period after DCC. AF burden is calculated based on continuous ECG monitoring using an insertable cardiac monitor (ICM). The primary efficacy analysis will be conducted on the modified intention-to-treat (mITT) population, whereas the safety analysis will be done on the safety population. Although ICMs have been used in other interventional studies to assess arrhythmia, PROMISE-AF will be the first study to assess antiarrhythmic efficacy and safety of a novel rhythm-stabilizing drug after DCC by using ICMs.
Keywords:OMT-28, Omega-3 Epoxyeicosanoid, Atrial Fibrillation, Phase II
Source:International Journal of Cardiology (IJC) Heart & Vasculature
ISSN:2352-9067
Publisher:Elsevier
Volume:29
Page Range:100573
Date:August 2020
Official Publication:https://doi.org/10.1016/j.ijcha.2020.100573
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library